FLGC vs. OVID, NBRV, GBIO, ELYM, ICCC, FBLG, NRXP, OCX, SPRO, and ESLA
Should you be buying Flora Growth stock or one of its competitors? The main competitors of Flora Growth include Ovid Therapeutics (OVID), Nabriva Therapeutics (NBRV), Generation Bio (GBIO), Eliem Therapeutics (ELYM), ImmuCell (ICCC), FibroBiologics (FBLG), NRx Pharmaceuticals (NRXP), OncoCyte (OCX), Spero Therapeutics (SPRO), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry.
Flora Growth vs.
Flora Growth (NASDAQ:FLGC) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Flora Growth presently has a consensus target price of $5.00, indicating a potential upside of 474.78%. Ovid Therapeutics has a consensus target price of $4.03, indicating a potential upside of 553.17%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ovid Therapeutics is more favorable than Flora Growth.
In the previous week, Flora Growth's average media sentiment score of 0.00 beat Ovid Therapeutics' score of -0.59 indicating that Flora Growth is being referred to more favorably in the media.
Ovid Therapeutics has lower revenue, but higher earnings than Flora Growth.
Flora Growth has a net margin of -30.99% compared to Ovid Therapeutics' net margin of -5,142.56%. Ovid Therapeutics' return on equity of -39.24% beat Flora Growth's return on equity.
Flora Growth has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.
36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 13.0% of Flora Growth shares are owned by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Ovid Therapeutics received 340 more outperform votes than Flora Growth when rated by MarketBeat users. Likewise, 70.86% of users gave Ovid Therapeutics an outperform vote while only 60.00% of users gave Flora Growth an outperform vote.
Summary
Ovid Therapeutics beats Flora Growth on 12 of the 16 factors compared between the two stocks.
Get Flora Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLGC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Flora Growth Competitors List
Related Companies and Tools
This page (NASDAQ:FLGC) was last updated on 2/22/2025 by MarketBeat.com Staff
Free FLGC Stock Alerts